Key Points
- Insider sale: Director Ruhi Ahmad Khan sold 6,938 shares at an average price of $1.96 for $13,598.48 on Feb. 24, leaving them with 104,998 shares (a 6.20% ownership decline).
- Analyst outlook mixed: The stock has two Buy and one Sell rating, an average consensus of "Hold" and an average price target of about $8, with recent upgrades from Citigroup and HC Wainwright.
- Company and market snapshot: Caribou is a clinical‑stage CRISPR gene‑editing biotech (co‑founded by Jennifer Doudna) with a market cap of ~$200M, the stock trading near $2 (12‑month range $0.66–$3.54) and high volatility (beta ~2.61); institutions own ~77.5%.
Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) insider Ruhi Ahmad Khan sold 6,938 shares of Caribou Biosciences stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $1.96, for a total value of $13,598.48. Following the sale, the insider directly owned 104,998 shares in the company, valued at approximately $205,796.08. This trade represents a 6.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Caribou Biosciences Stock Up 11.5%
Caribou Biosciences stock opened at $2.14 on Wednesday. The business has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.90. Caribou Biosciences, Inc. has a 12 month low of $0.66 and a 12 month high of $3.54. The stock has a market cap of $200.03 million, a price-to-earnings ratio of -1.26 and a beta of 2.61.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. R Squared Ltd bought a new stake in Caribou Biosciences during the 3rd quarter worth approximately $29,000. Bronte Capital Management Pty Ltd. acquired a new position in Caribou Biosciences in the fourth quarter worth $25,000. Liberty Wealth Management LLC acquired a new position in Caribou Biosciences in the third quarter worth $45,000. Next Capital Management LLC bought a new stake in shares of Caribou Biosciences during the second quarter worth $25,000. Finally, Creative Planning acquired a new stake in shares of Caribou Biosciences in the second quarter valued at $25,000. 77.51% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. Citigroup lifted their target price on shares of Caribou Biosciences from $5.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, November 3rd. Truist Financial set a $7.00 price objective on Caribou Biosciences in a report on Tuesday, November 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Wednesday, January 21st. Finally, HC Wainwright increased their target price on Caribou Biosciences from $3.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $8.00.
Get Our Latest Stock Report on CRBU
Caribou Biosciences Company Profile
(
Get Free Report)
Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company's core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.
Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
